Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
about
Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosisTargeting cellular metabolism to improve cancer therapeuticsGrb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxelNovel approaches to target HER2-positive breast cancer: trastuzumab emtansineNeoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumabA paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyDual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugsAutophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumabCancer genome sequencing: understanding malignancy as a disease of the genome, its conformation, and its evolution.Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerHER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancerQuantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transferSmall activating RNA restores the activity of the tumor suppressor HIC-1 on breast cancerNetwork analysis of breast cancer progression and reversal using a tree-evolving network algorithmComparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopesNovel inhibitors of a Grb2 SH3C domain interaction identified by a virtual screenBreast Cancer Prognostics Using Multi-Omics Data.Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stabilitytabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO)Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis.Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancerEnhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cellsImmunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathwaysExosomal Proteome Profiling: A Potential Multi-Marker Cellular Phenotyping Tool to Characterize Hypoxia-Induced Radiation Resistance in Breast Cancer.Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.Genome profiling of ERBB2-amplified breast cancers.Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.Trastuzumab emtansine: mechanisms of action and drug resistancePhotodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins.Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model systemActivation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathwayHyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer.Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status.Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer
P2860
Q21132316-EA1700A0-53E1-472F-973B-D0E195CBCBB0Q24596727-840184CD-704F-413A-8145-0D55889725CAQ24658331-2DA8DFF5-26DE-4E57-B230-C93AC7AE35FCQ26747729-4240AF6A-73C5-400C-8D46-DDE68FB5B14EQ26764879-633A6E21-B108-4D87-8357-5B3623EE5F40Q26824462-C2AD2EEF-E755-42D6-BBB7-7D62D612B460Q27303674-BC57ECCC-0B3F-4037-BCA0-CD9D1A165B73Q27346475-E8AAA0C9-E265-4147-AA3C-9387E0B9FD07Q27690285-D1B9B451-678B-41DE-9461-B95F70A95D7AQ27851528-95C79522-E5C6-4F72-B05C-6BCAF274E90DQ27851582-6D1F17AA-759F-4E4E-99D9-65BAC0598D57Q28072513-1D42F822-F011-4B1F-A175-9BC4DFC2DF51Q28085413-D1DAA597-87EE-47CF-BECC-56257116FC1AQ28481420-85EEF502-C9B9-4CC6-8126-E25AF2E34188Q28539229-4C5BE494-22CC-47FF-B4C7-9D0A38ACD097Q28541114-4639D393-B479-400D-BC9E-C7D4FC888954Q28542825-3322C59B-C1C4-45B5-98BE-BAA50E72ACD3Q30009971-345D33AD-4F5E-4248-B4D0-A974022FF33DQ31124796-86985A12-97F0-41F6-8627-3FB37F762CB1Q31129446-3EF9C450-80D7-40C0-9B89-422748B7562AQ33284158-2F19DBF8-5078-464D-96C1-3A348F6DD5CDQ33373850-0F238B9A-9D8A-47EC-8EB0-59031FC5F22DQ33394374-0E2AFFF9-098B-4695-92A3-60B141B7340EQ33430735-D2337CCF-3DB4-4E3B-9E00-B24CC363BB1FQ33511035-7AB68F3D-A68B-4927-8848-616ADBB75CEAQ33533628-C8D4E0A8-6884-4B7F-A322-0183BCE41939Q33538332-34C625CE-DC9A-4647-B9B0-0022EE6D41BDQ33576327-D8E071FC-1BFD-4314-96C9-C96CF3DB5452Q33584432-809840E4-6160-4F4E-BEB9-66F9611ED823Q33644570-8F30997F-D014-4A5D-B0C0-F63047FAD231Q33668653-D6D65CEF-6B9F-4E16-BCD8-4B6242716401Q33713239-BBBA99F6-0823-4E7A-B39A-646F9A7A7939Q33743601-16BD676F-9F05-4D61-B3C4-13AACD72A016Q33759627-12087813-8C80-416F-BACE-A1353B37F232Q33765280-E9F28666-9DDE-4ED3-89FD-7EBE6317CF5AQ33769117-F78396C2-50A4-474C-81F9-A196ED0D44A2Q33880386-78B334B5-828C-4450-A4C3-FF45BF5E6F7BQ33887610-2B09589A-DC01-45C0-BDE1-95347DD47685Q33927261-396DF6C8-3A12-4B5E-AEC6-B8747D579163Q33942512-E11C6144-97B5-4186-B25A-254526AE2928
P2860
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Mechanisms of disease: underst ...... herapy in human breast cancer.
@ast
Mechanisms of disease: underst ...... herapy in human breast cancer.
@en
type
label
Mechanisms of disease: underst ...... herapy in human breast cancer.
@ast
Mechanisms of disease: underst ...... herapy in human breast cancer.
@en
prefLabel
Mechanisms of disease: underst ...... herapy in human breast cancer.
@ast
Mechanisms of disease: underst ...... herapy in human breast cancer.
@en
P2093
P2860
P356
P1476
Mechanisms of disease: underst ...... herapy in human breast cancer.
@en
P2093
Francisco J Esteva
Gabriel N Hortobagyi
Mien-Chie Hung
Rita Nahta
P2860
P2888
P304
P356
10.1038/NCPONC0509
P577
2006-05-01T00:00:00Z
P5875
P6179
1053491584